Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19621189 | 0.88 | CNR1 (0.60) | CNR1FAAHALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL11525698 | 0.88 | CNR1 (0.56) | CNR1FAAHCASP2MAPTNAAA | |
| SCHEMBL13938722 | 0.87 | MAPT (0.48) | CNR1FAAHCASP2ALDH1A1TSHR | |
| SCHEMBL18926538 | 0.85 | ALDH1A1 (0.62) | CNR1FAAHALDH1A1MAPTEPHX2 | |
| SCHEMBL13869001 | 0.85 | ALDH1A1 (0.62) | CNR1FAAHALDH1A1MAPTEPHX2 | |
| SCHEMBL22856074 | 0.85 | MAPT (0.46) | CNR1FAAHCASP2ALDH1A1TSHR | |
| SCHEMBL12240644 | 0.83 | CASP2 (0.53) | CNR1FAAHCASP2TSHRSMN1; SMN2 | |
| SCHEMBL11525869 | 0.83 | — | — | |
| SCHEMBL13528442 | 0.81 | CNR1 (0.53) | CNR1FAAHALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL26728693 | 0.80 | CNR1 (0.41) | CNR1FAAHALDH1A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022115651-A1 | USE OF CYCLOSPORINE ANALOGUES AS ANTITHROMBOTIC AGENTS | HEPION PHARMACEUTICALS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220168385-A1 | USE OF CYCLOSPORINE ANALOGUES AS ANTITHROMBOTIC AGENTS | ACHILLE LIFE SCIENCES LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| EP-3461835-A1 | CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3 | ContraVir Pharmaceuticals, Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| WO-2018106928-A1 | TREATMENT AND PREVENTION OF HBV DISEASES BY CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACIDES 1 AND 3 | CONTRAVIR PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-9714271-B2 | Cyclosporine analogue molecules modified at amino acid 1 and 3 | CONTRAVIR PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160207961-A1 | Cyclosporine Analogue Molecules Modified At Amino Acid 1 and 3 | ACHILLE LIFE SCIENCES LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-9200038-B2 | Cyclosporine analogue molecules modified at amino acid 1 and 3 | CICLOFILIN PHARMACEUTICALS CORP. (CA) | 2015-12-01 | — | — | US | disclosed |
| US-20140142033-A1 | CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3 | ISOTECHNIKA PHARMA INC. (CA) | 2014-05-22 | — | — | US | disclosed |
| US-20130190223-A1 | NONIMMUNOSUPPRESSIVE CYCLOSPORINE ANALOGUE MOLECULES | ISOTECHNIKA PHARMA INC. (CA) | 2013-07-25 | — | — | US | disclosed |
| WO-2012079172-A1 | CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3 | ISOTECHNIKA PHARMA INC. (CA) | 2012-06-21 | — | — | WO | disclosed |
| WO-2010012073-A1 | NONIMMUNOSUPPRESSIVE CYCLOSPORINE ANALOGUE MOLECULES | ISOTECHNIKA LABS INC. (CA) | 2010-02-04 | — | — | WO | disclosed |
| US-4179292-A | Light-sensitive copying composition | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190223-A1 | NONIMMUNOSUPPRESSIVE CYCLOSPORINE ANALOGUE MOLECULES | CD40, FKBP1A, FKBP4 | CNR1 86/4885FAAH 82/4885CASP2 3278/4885 |
| US-20160207961-A1 | Cyclosporine Analogue Molecules Modified At Amino Acid 1 and 3 | FKBP1A, CHP1, FKBP3 | CNR1 855/4885FAAH 2178/4885CASP2 3239/4885 |
| US-20220168385-A1 | USE OF CYCLOSPORINE ANALOGUES AS ANTITHROMBOTIC AGENTS | SERPINC1, CHP1, FGB | CNR1 899/4885FAAH 3572/4885CASP2 1978/4885 |
| US-20140142033-A1 | CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3 | FKBP1A, CHP1, FKBP3 | CNR1 855/4885FAAH 2178/4885CASP2 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.